United States - English - NLM (National Library of Medicine)

physicians total care, inc. - besifloxacin (unii: bfe2nbz7nx) (besifloxacin - unii:bfe2nbz7nx) - besifloxacin 6 mg in 1 ml - besivance™ (besifloxacin ophthalmic suspension) 0.6%, is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: cdc coryneform group g corynebacterium pseudodiphtheriticum* corynebacterium striatum* haemophilus influenzae moraxella lacunata* staphylococcus aureus staphylococcus epidermidis staphylococcus hominis* staphylococcus lugdunensis* streptococcus mitis group streptococcus oralis streptococcus pneumoniae streptococcus salivarius* *efficacy for this organism was studied in fewer than 10 infections. none pregnancy category c. oral doses of besifloxacin up to 1000 mg/kg/day were not associated with visceral or skeletal malformations in rat pups in a study of embryo-fetal development, although this dose was associated with maternal toxicity (reduced body weight gain and food consumption) and maternal mortality. increased post-implantation loss, decreased fetal body weights, and decreased fetal ossification were also observed. at this dose, the mean

Canada - English - Health Canada

bausch & lomb inc - besifloxacin (besifloxacin hydrochloride) - suspension - 0.6% - besifloxacin (besifloxacin hydrochloride) 0.6% - antibacterials

Australia - English - Department of Health (Therapeutic Goods Administration)

bausch & lomb australia pty ltd - besifloxacin, quantity: 6.06 mg/ml - eye drops, suspension - excipient ingredients: mannitol; water for injections; disodium edetate; benzalkonium chloride; poloxamer; polycarbophil; sodium hydroxide; sodium chloride - besivance is indicated for the treatment of severe, confirmed bacterial conjunctivitis caused by besifloxacin sensitive bacteria. besivance is indicated for adults and children 12 months and older.

United States - English - NLM (National Library of Medicine)

bausch & lomb incorporated - besifloxacin (unii: bfe2nbz7nx) (besifloxacin - unii:bfe2nbz7nx) - besivance® (besifloxacin ophthalmic suspension) 0.6% is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: aerococcus viridans* cdc coryneform group g corynebacterium pseudodiphtheriticum* corynebacterium striatum* haemophilus influenzae moraxella catarrhalis* moraxella lacunata* pseudomonas aeruginosa* staphylococcus aureus staphylococcus epidermidis staphylococcus hominis* staphylococcus lugdunensis* staphylococcus warneri* streptococcus mitis group streptococcus oralis streptococcus pneumoniae streptococcus salivarius* *efficacy for this organism was studied in fewer than 10 infections. none. risk summary there are no available human data for the use of besivance during pregnancy to inform any drug-associated risks; however, systemic exposure to besifloxacin from ocular administration is low [see clinical pharmacology (12.3)]. oral administration of besifloxacin to pregnant rats during organogenesis or during the prenatal and postnatal per

Singapore - English - HSA (Health Sciences Authority)

bausch & lomb (singapore) private limited - besifloxacin hcl 6.63mg/ml eqv besifloxacin base - suspension, sterile - 6 mg/ml - besifloxacin hcl 6.63mg/ml eqv besifloxacin base 6 mg/ml

United States - English - NLM (National Library of Medicine)

a-s medication solutions - besifloxacin (unii: bfe2nbz7nx) (besifloxacin - unii:bfe2nbz7nx) - besivance® (besifloxacin ophthalmic suspension) 0.6% is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: aerococcus viridans* cdc coryneform group g corynebacterium pseudodiphtheriticum* corynebacterium striatum* haemophilus influenzae moraxella catarrhalis* moraxella lacunata* pseudomonas aeruginosa* staphylococcus aureus staphylococcus epidermidis staphylococcus hominis* staphylococcus lugdunensis* staphylococcus warneri* streptococcus mitis group streptococcus oralis streptococcus pneumoniae streptococcus salivarius* *efficacy for this organism was studied in fewer than 10 infections. none. risk summary there are no available human data for the use of besivance during pregnancy to inform any drug-associated risks; however, systemic exposure to besifloxacin from ocular administration is low [see clinical pharmacology (12.3)]. oral administration of besifloxacin to pregnant rats during organogenesis or during the prenatal and postnatal per

Philippines - English - FDA (Food And Drug Administration)

bausch & lomb philippines inc. - besifloxacin hydrochloride - suspension, ophthalmic - 6mg/ml (60% w/v)

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

bausch & lomb (malaysia) sdn. bhd. - besifloxacin hcl salt -

Bangladesh - English - DGDA (Directorate General of Drug Administration)

aristopharma limited - besifloxacin - eye drops - .6 gm/100 ml

Bangladesh - English - DGDA (Directorate General of Drug Administration)

asiatic laboratories ltd. - besifloxacin - eye drops - .6 gm/100 ml